1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I think the ASX healthcare stock Sonic Healthcare Ltd (ASX: SHL) looks very undervalued. It's so cheap that I'm thinking about buying some Sonic Healthcare shares myself.

The Sonic Healthcare share price has fallen more than 15% in the past year and it's down around 25% since April 2023.

This global pathology business is one to look into, in my opinion.

I love investing in growing businesses where the share price has dropped because this means the price/earnings (P/E) ratio has reduced and is usually more attractive.

Multiple growth avenues

COVID-19 testing revenue has almost entirely gone, which has reduced the company's operating leverage.

But, the FY24 first-half result demonstrated a number of the positives that I like about the business.

For starters, it reported base business revenue growth (which excludes COVID-19 testing) of 15%. Its organic revenue growth was 6.2% (which excludes things like acquisitions), which is a solid core business growth rate.

The base business is benefiting from different tailwinds, like a growing population, which means there are more potential patients, while an older population could increase the frequency that services are required.   

Sonic Healthcare is regularly investing in making new acquisitions, which can boost its scale – this can increase the profit margins. Around A$500 million of new annual revenue has been secured from acquisitions and contract wins, including $175 million from Synlab Suisse and $265 million from German acquisitions.

The ASX healthcare stock also said its cost reduction programs are "well advanced", which could be beneficial for margins in future reporting periods.

Sonic Healthcare can benefit from several new technology sources, including PathologyWatch, AI, and its involvement with Microba Life Sciences Ltd (ASX: MAP), to help its future earnings.

Growing dividend

I don't know for sure what the Sonic Healthcare share price is going to do. But, the ASX healthcare stock's ongoing dividend growth can provide 'real' returns while we wait for a recovery. It said it has a progressive dividend policy.

According to the estimate on Commsec, the company could pay an annual dividend per share of $1.08, which would translate into a forward dividend yield of 4%, excluding franking credits.

Appealing valuation

After the recent decline of the Sonic Healthcare share price, it's now valued at under 19 times FY25's estimated earnings, which I think is very reasonable for a business in a defensive industry like healthcare.

Due to its fairly large market capitalisation size, I'm not expecting huge gains, but I believe it can be a steady compounder and outperform the S&P/ASX 200 Index (ASX: XJO) over the long term, at the current Sonic Healthcare share price. I'm thinking about buying some Sonic Healthcare shares for my own portfolio at the current level when Motley Fool's trading rules allow me to.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »